Anirban Maitra, Laura and Isaac Perlmutter Professor of Pathology and Director of the Perlmutter Cancer Center, shared The Lustgarten Foundation’s post on LinkedIn, adding:
“Super excited to receive this Clinical Accelerator Initiative (CAI) grant from The Lustgarten Foundation to intercept Pancreatic Cancer by targeting KRAS and have NYU Langone Health lead the multi-institutional clinical trial.
An exciting time for the field. Thank you so much.”
Quoting The Lustgarten Foundation’s post:
“Four new grants. Four bold approaches to advancing pancreatic cancer care.
The Lustgarten Foundation has announced the 2026 recipients of the Dr. Robert F. Vizza Lustgarten Clinical Accelerator Initiative, which supports smarter, science-driven clinical trials designed to move promising research into the clinic faster.
This year’s recipients are:
- Ashwin Somasundaram, MD, of the The University of North Carolina at Chapel Hill;
- Harshabad Singh, MBBS, MD, of Mass General Brigham Cancer Institute;
- Mark O’Hara, MD, of the University of Pennsylvania;
- Anirban Maitra, MD, of NYU Langone Health Perlmutter Cancer Center.
Their studies will explore targeted treatment, immunotherapy, biomarker-guided care, and a first-of-its-kind approach to intercept pancreatic cancer before it develops.”
Other articles about The Lustgarten Foundation on OncoDaily.
